Takeda Recognized as a Global 100 Most Sustainable Corporation for Fourth Consecutive Year

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) is proud to be named by Corporate Knights as one of the 2019 Global 100 Most Sustainable Corporations in the World (Global 100) for the fourth consecutive year. 

Takeda is one of top 1.3% corporate sustainability performers in the world to be listed. This distinction is based on 21 key performance indicators, with notable recognition of environmental and employee management, along with robust corporate governance structure and proactive information disclosure. 

The Index launched in 2005; results are disclosed annually at the World Economic Forum in Davos.

“We are honored to be recognized once again for our deep-rooted and long-term commitment to sustainability,” said Christophe Weber, President and CEO. “As a patient-centric, global, values-based R&D-driven biopharmaceutical company and responsible global corporate citizen, our charge naturally extends from life-changing medicines to building sustainable value. We do this through dedicated Corporate Social Responsibility (CSR) activities, such as our Global CSR Program, which partners with organizations to improve the health of people worldwide through disease prevention, capacity building and long-term commitment. We are also constantly working to create and preserve economic, environmental, and social value for society beyond CSR. Multi-year recognition for these efforts by Corporate Knights galvanizes us to continue striving for even greater impact.”

In addition to the Global 100 Index, Takeda is recognized by multiple Environment, Social and Governance (ESG) Investment valuations. As a long-standing member of the United Nations Global Compact, Takeda’s established track record in sustainability is guided by key international targets, such as the Sustainable Development Goals (SDGs).

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com